Targeted alpha therapy with Bi-213 and Ac-225
The molecularly targeted treatment of cancerous tumors by the alpha-emitting radionuclides 213Bi and 225Ac has shown remarkable efficacy in clinical trials. Ultimately, this treatment option will be applicable to a wide range of cancers and other diseases, subject to the
development of specific radioligands. Currently 225Ac is mainly being produced from the decay of existing stocks of 229Th. The expected wider application for radiotherapy will require many orders of magnitude more radionuclide than can currently be produced. Consequently, various alternative production methods are being pursued.
KELLERBAUER Alban;
BRUCHERTSEIFER Frank;
MALMBECK Rikard;
MORGENSTERN Alfred;
2021-11-03
INSTITUTE OF PHYSICS
JRC118274
1742-6588 (online),
https://iopscience.iop.org/article/10.1088/1742-6596/1643/1/012205,
https://publications.jrc.ec.europa.eu/repository/handle/JRC118274,
10.1088/1742-6596/1643/1/012205 (online),
Additional supporting files
| File name | Description | File type | |
|---|
